Nsab, Filial Af Neurosearch Sweden Ab, Sverige

A. Carlsson Research Ab

Teva Pharmaceuticals International Gmbh

Nsab, Filial Af Neurosearch Ab, Sverige

Neurosearch Sweden Ab

Integrative Research Laboratories Sweden Ab

Nicholas Ross Waters

Clas Sonesson

Lars Swanson

Susanna Waters

Joakim Tedroff

Ingela Marianne Svan

Fredrik Pettersson

Bengt Andersson

Ingela Marianne Svan, Legal Representative

Anders Kristoffer Lilja, Legal Representative

Liselott Lilja Rönnqvist, Legal Representative

Jenny Maria Carlberg, Legal Representative

Anders Kristoffer Lilja

Liselott Lilja Rönnqvist

Jenny Maria Carlberg

New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; Ris OSOCF, OSOCH, SOR, SOR, COR, NO, or CONHRand when X is CH or C Rmay also be CF, CN, F, Cl, Br, or I; Ris a C-Calkyl, an allyl, CHSCH, CHCHOCH, CHCHCHF, CHCF, 3,3,3-trifluoropropyl, 4,4,4,-trifluorobutyl, or &#x2014;(CH)&#x2014;R; Ris a C-Calkyl CF, or N(R); Ris a C-Ccycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed

Modulators of dopamine neurotransmission

The present invention relates to compounds which have therapeutic effects against disorders in the central nervous system, and in particular new 4-(ortho,meta-disubstituted phenyl)-1-alkypiperidines and piperazines. wherein R1, R2, R3 and X are as defined.

Disubstituted phenylpiperdines/piperazines as modulators of dopamine neurotransmission

The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1-pyrrolidinols for the treatment of central nervous system disorders.

Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

The present invention relates to compounds which have therapeutic effects against disorders in the central nervous system, and in particular new 4-(ortho,meta-disubstituted phenyl)-1-alkypiperidines. wherein R1, R2, and R3 are as defined.

Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission

The present invention relates to compounds which have therapeutic effects against disorders in the central nervous system, and in particular new 4-(ortho, meta-disubstituted phenyl)-1-alkypiperidines and piperazines. wherein R, R, Rand X are as defined.

Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission

The present invention relates to compounds having therapeutic effects against disorders in the central nervous system, and in particular substituted hydroxypiperidines of the formula 1: wherein R1, R2, and R3 are as defined herein.

Substituted piperidines as modulators of dopamine neurotransmission

A 3-substituted 4-(phenyl-N-alkyl)-piperazine compound of the following formula: wherein Ris selected from the group consisting of OSOCF, OSOCH, SOR, COCF, COCHand COCHCH, wherein Ris as defined hereafter; Ris selected from the group consisting of C-Calkyls, allyl, CHCHCHF, CHCF, 3,3,3-trifluoropropyl and 4,4,4-trifluorobutyl; Ris selected from the group consisting of C-Calkyls, CF, and N(CH); with the proviso that when Ris SORand Ris a C-Calkyl, then Ris not CHCHOCH; or a pharmaceutically acceptable salt thereof are provided. Also, pharmaceutical compositions comprising the above compound and methods wherein the above compound is used for the treatment of various disorders are provided.

New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1) wherein X is N, CH, or C, however X may only be C when the compound comprises a double bind at the dotted line; Ris CF, OSOCF, OSOCH, SOR, SOR, COR, CN, OR, NO, CONHR, 3-thiophene, 2-thiophene, 3-furane, 2-furane, F, Cl, Br, or I; Ris F, Cl, Br, I, CN, CF, CH, OCH, OH, and NH; Rand Rare independently H or a C-Calkyl; Ris a C-Calkyl, an allyl, CHSCH, CHCHOCH, CHCHCHF, CHCF, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, or &#x2014;(CH)R; Ris a C-Ccycloalkyl, 2-tetrahydrofurane, or 3-tetra-hydrofurane; Ris a C-Calkyl, CF, or N(R), and pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed.

Growing community of inventors

Gothenburg, Sweden

Nicholas Ross Waters